Skip to main content
Clinical Trials/JPRN-UMIN000008465
JPRN-UMIN000008465
Completed
N/A

PhaseII study of neoadjuvant chemotherapy with the nab Paclitaxel And Trastuzumab followed by FEC for the HER2-positive resectable primary breast cancer - PhaseII study of neoadjuvant chemotherapy with the nab Paclitaxel And Trastuzumab followed by FEC for the HER2-positive resectable primary breast cancer

Osaka Breast Cancer Chemo-Endocrine Therapy Study Group0 sites30 target enrollmentJuly 18, 2012

Overview

Phase
N/A
Intervention
Not specified
Conditions
HER2 positive resectable primary breast cancer
Sponsor
Osaka Breast Cancer Chemo-Endocrine Therapy Study Group
Enrollment
30
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 18, 2012
End Date
April 30, 2017
Last Updated
2 years ago
Study Type
Interventional
Sex
Female

Investigators

Sponsor
Osaka Breast Cancer Chemo-Endocrine Therapy Study Group

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\. Current history of malignant neoplasm. 2\. Bilateral invasive breast cancer. 3\. Cases who does not wish to undergo an operation after neoadjuvant chemotherapy. 4\. Patients with medical conditions that renders them intolerant to primary chemotherapy and related treatment, including infection, diarrhea, intestinal paralysis, severe Diabetes Mellitus. 5\. Has history of hypersensitivity reaction in important drug of this study. 6\. Positive for HBs antigen. 7\. 8\. With severe peripheral neuropathy. 9\. Transfusion within the past 2 weeks. 10\. With the history of severe mental disease or under treatment. 11\. With active pleural effusion or ascites. 12\. Pregnancy, or suspected pregnancy. 13\. Cases who physician judged improper to entry this trial.

Outcomes

Primary Outcomes

Not specified

Similar Trials